Trulicity vs Mounjaro: Lilly's Old and New Weekly

Trulicity (dulaglutide, Eli Lilly) vs Mounjaro (tirzepatide, Eli Lilly)

Last verified November 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The verdict

Same manufacturer, successive generations. SURPASS-2 put Mounjaro 15 mg at −11.2 kg over 40 weeks, against semaglutide rather than Trulicity; in AWARD-11, Trulicity 1.5 mg lost about 3.0 kg over 36 weeks, so the two figures come from different trials. Both now have cardiovascular results: Trulicity has REWIND's MACE −12% against placebo, and in SURPASS-CVOT (NEJM, December 2025) Mounjaro was noninferior to Trulicity itself. Trulicity lists at about $1,007 a month and Mounjaro at about $1,112; LillyDirect sells them for cash at $389 and $499, and both savings cards are restricted to commercial insurance. Trulicity's remaining case is its placebo-controlled outcomes result and a step-therapy requirement that may put it first anyway.

Side-by-side comparison

Trulicity vs Mounjaro, side by side
FieldTrulicityMounjaro
MechanismGLP-1 receptor agonistDual GIP / GLP-1 receptor agonist
A1C reduction (max dose, cross-trial)−1.1% / 26 wk (Trulicity 1.5 mg, AWARD program)−2.30% / 40 wk (Mounjaro 15 mg, SURPASS-2)
Weight loss (max dose, cross-trial)−1.3 to −3.0 kg / 26 wk (Trulicity 1.5 mg, US label)−11.2 kg / 40 wk (Mounjaro 15 mg, SURPASS-2)
Insulin-comparator head-to-headNo direct insulin-degludec head-to-head at max dose−2.37% A1C vs insulin degludec −1.34% (SURPASS-3, 52 wk)
DosingOnce-weekly subq 0.75 → 1.5 → 3 → 4.5 mg penOnce-weekly subq 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg
FDA-approved indicationType 2 diabetes (adults + pediatrics ≥10); CV risk reduction in T2DType 2 diabetes (adults only)
Cardiovascular outcomeMACE −12% (REWIND, HR 0.88; in T2D ± established CVD)SURPASS-CVOT (2025): noninferior to dulaglutide (HR 0.92); MACE indication on the label
Youngest approved age10 and over, since 2022Adults only
What it costs if you pay cash$389/mo via LillyDirect self-pay at every strength (list about $1,007), with a patient-assistance route and a commercial savings card$499/mo via LillyDirect self-pay at every strength

What each one costs in the compounded market

Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.

Trulicity — dulaglutide

No seller on this register publishes a compounded price for it. For a drug still in trials that is expected — and anyone selling it anyway is doing so outside the system this register covers.

Mounjaro — tirzepatide

from $69 /mo

453 sellers publish a standing price. This is the lowest of all 453; the median is $228.28 a month.

Where to get tirzepatide — a selection of sellers, not a price ranking

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Which works better for weight loss, Trulicity or Mounjaro?

On the trial evidence, Mounjaro. Trulicity recorded −1.3 to −3.0 kg / 26 wk (Trulicity 1.5 mg, US label) and Mounjaro −11.2 kg / 40 wk (Mounjaro 15 mg, SURPASS-2), and the head-to-head comparison put Trulicity at No direct insulin-degludec head-to-head at max dose against Mounjaro at −2.37% A1C vs insulin degludec −1.34% (SURPASS-3, 52 wk). A head-to-head is the strongest form of this evidence because both arms run under one protocol — separate trials are not directly comparable however alike they look.

Are Trulicity and Mounjaro the same drug?

No. Trulicity is dulaglutide and Mounjaro is tirzepatide — different molecules, and they work differently: GLP-1 receptor agonist against Dual GIP / GLP-1 receptor agonist. Results with one do not predict results with the other.

Is Trulicity or Mounjaro cheaper?

On the manufacturers' own cash pricing: Trulicity at $389/mo via LillyDirect self-pay at every strength (list about $1,007), with a patient-assistance route and a commercial savings card, Mounjaro at $499/mo via LillyDirect self-pay at every strength. That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

Does either one have better cardiovascular evidence?

Trulicity does. Trulicity: MACE −12% (REWIND, HR 0.88; in T2D ± established CVD). Mounjaro: SURPASS-CVOT (2025): noninferior to dulaglutide (HR 0.92); MACE indication on the label. This matters more than it first appears — a drug with a completed outcomes trial has evidence about events that matter, not only about weight, and that is often what decides coverage.

How is each one taken?

Trulicity: Once-weekly subq 0.75 → 1.5 → 3 → 4.5 mg pen. Mounjaro: Once-weekly subq 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Worth weighing honestly against your own habits — the best drug for you is partly the one you will still be taking in eight months, and a dosing routine that does not fit a life gets abandoned.

What does a compounded version of each actually cost?

Across the 734 sellers in this register, the cheapest standing monthly cash prices we hold are tirzepatide from $69 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Trulicity to Mounjaro?

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647.
  2. 2.Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021. PMID: 34370970.
  3. 3.Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. PMID: 31189511.
  4. 4.Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018. PMID: 29910024.
  5. 5.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — FDA prescribing information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  6. 6.Eli Lilly and Company. TRULICITY (dulaglutide) injection — FDA prescribing information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
  7. 7.Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes N Engl J Med. 2025. PMID: 41406444.
  8. 8.Frias JP, et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) Diabetes Care. 2021. PMID: 33397768.

See the full drug-vs-drug verdict index or provider rankings.